A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
← catalyst calendarNCT07733765 · readout in 616 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
336estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-31 | estimated | When the study began enrolling |
| Primary completion | 2028-04-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-27 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alopecia Areata
Interventions
- Drug: Ritlecitinib 100 mg
- Drug: Ritlecitinib 50 mg
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFDifference in the proportion of Severity of Alopecia Tool (SALT) 0 responders at Week 24 between ritlecitinib 50 mg QD versus placebo
measured Week 24
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed